在B型血友病中,单阶段凝血和染色体因子IX活性之间的差异的临床影响
David E Schmidt1,2, Åsa Truedsson3, Annelie Strålfors3,4
1Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Thrombosis and haemostasis
|July 26, 2023
概括
第九因子活性 (FIX:C) 测定显示出B型血友病患者的异常. 使用基因类型的单阶段 (OSA) 和染色体 (CSA) 测定对于准确的严重程度分类和管理至关重要.
科学领域:
- 血液学 血液学 血液学
- 临床化学 临床化学
- 遗传学 是一个遗传学.
背景情况:
- 一个阶段测定 (OSA) 和染色基质测定 (CSA) 之间的因子IX活性 (FIX:C) 测量的差异使B型血友病 (PwHB) 患者的临床管理复杂化.
- 准确的FIX:C评估对于确定疾病严重程度和指导治疗策略至关重要.
研究的目的:
- 调查轻度至中度血友病患者的OSA和CSA测量FIX:C水平的差异.
- 为了评估这些测试差异对血友病B严重程度分类的影响.
- 探索FIX:C差异和患者基因型之间的相关性.
主要方法:
- 一项单中心研究涉及21名血友病B型基因型患者.
- 使用OSA (ActinFSL,西门子) 和CSA (Biophen,Hyphen) 进行FIX:C测量.
- 实验室内实验与野生类型FIX和CSA的实验室间可再生性评估进行.
主要成果:
- 与OSA相比,CSA始终产生了较低的FIX:C值.
- 当被CSA评估时,很大一部分患者 (10/17) 被归类为更严重的血友病B类别.
- 观察到差异,特别是在低FIX:C水平 (<0.10 IU/mL) 时,OSA更好地反映了临床出血严重程度. 患有FIX血清蛋白酶域中的误解变异的患者表现出两倍的差异.
- 在三个欧洲实验室中,CSA表现出极好的可重复性.
结论:
- 与CSA相比,FIX:C测量在OSA中始终更高.
- 仅仅依靠CSA可能导致错误分类血友病B严重程度.
- 将OSA和CSA结果与基因定型结合起来,可以提供一种更全面的方法来分类B型血友病的严重程度,并为临床管理提供信息.
相关概念视频
Disorders of Hemostasis
992
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
992
Anticoagulant Drugs: Low-Molecular-Weight Heparins
755
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
755
Extrinsic and Intrinsic Pathways of Hemostasis
8.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.3K
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Coagulation
7.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.1K


